Drug Trial Radar · NCT06676319
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
556
Actual
Start
Nov 7, 2024
Primary completion
Jun 21, 2027
Study completion Jul 19, 2027
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Nov 6, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel-group, Phase 2, randomized, double-blind, placebo-controlled, 2-arm study for the treatment of asthma. The purpose of this study is to assess the efficacy, safety, and tolerability of add-on therapy with subcutaneous (SC) lunsekimig compared with placebo in male and female participants (aged 18 to 80 years, inclusive) with asthma, who are not currently eligible for biologic treatments. Study details include: * The study duration will be approximately 64 weeks for participants not transitioning into the LTS study and approximately 60 weeks for participants transitioning into the LTS study. * The investigational treatment duration will be up to approximately 52 weeks. * The number of visits will be 18.
Conditions
- Asthma
Interventions
LunsekimigDrug
Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection
Short-Acting Beta Agonists (SABA)Drug
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation
PlaceboDrug
Pharmaceutical form: Solution for injection in vial; Route of administration: Subcutaneous injection
Fluticasone/SalmeterolDrug
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration:Oral Inhalation
Budesonide/FormoterolDrug
Pharmaceutical form: Varies and depends on pharmaceutical presentation; Route of administration: Oral Inhalation
Budesonide/AlbuterolDrug
Pharmaceutical form: Aerosol for inhalation; Route of administration: Oral Inhalation
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of asthma exacerbation eventsTime frame: From baseline up to 52 weeks
Locations
221 sites in 22 countries. Site status is shown where the registry gives one.
The Center for Clinical Trials - Saraland- Site Number : 8400096
Saraland, Alabama
Chandler Clinical Research Trials- Site Number : 8400075
Chandler, Arizona
Epic Medical Research - Sun City- Site Number : 8400052
Sun City, Arizona
Tucson Clinical Research Institute- Site Number : 8400085
Tucson, Arizona
Ark Clinical Research- Site Number : 8400097
Long Beach, California
Downtown L.A. Research Center- Site Number : 8400080
Los Angeles, California
Carbon Health - North Hollywood - NoHo West- Site Number : 8400061
North Hollywood, California
Carbon Health - San Mateo - Hillsdale Mall- Site Number : 8400062
San Mateo, California
Stanford University Medical Center- Site Number : 8400108
Stanford, California
Modena Allergy And Asthma- Site Number : 8400068
Torrance, California
Howard University Hospital- Site Number : 8400107
Washington D.C., District of Columbia
Helix Biomedics- Site Number : 8400005
Boynton Beach, Florida
Beautiful Minds Clinical Research Center- Site Number : 8400019
Cutler Bay, Florida
Omega Research Consultants - Debary - North Charles Richard Beall Boulevard- Site Number : 8400082
DeBary, Florida
Alfa Medical Research- Site Number : 8400071
Hollywood, Florida
Royal Clinical Trials - Inverness- Site Number : 8400067
Inverness, Florida
Premier Medical Associates- Site Number : 8400077
Lady Lake, Florida
D&H Pompano Research Center- Site Number : 8400072
Margate, Florida
Research Institute of South Florida- Site Number : 8400023
Miami, Florida
Innovations Biotech- Site Number : 8400044
Miami, Florida
Tellabio International Research Services- Site Number : 8400083
Pembroke Pines, Florida
Avanza Medical Research Center- Site Number : 8400056
Pensacola, Florida
Ilumina Medical Research- Site Number : 8400095
Saint Cloud, Florida
Private Practice - Dr. David Kavtaradze- Site Number : 8400081
Cordele, Georgia
EmVenio Research - Riverdale- Site Number : 8400109
Riverdale, Georgia
Christie Clinic in Champaign on University- Site Number : 8400003
Champaign, Illinois
University of Kansas Medical Center- Site Number : 8400105
Kansas City, Kansas
Velocity Clinical Research - Rockville (formerly Meridian Clinical Research)- Site Number : 8400036
Rockville, Maryland
Javara - Privia Medical Group - Silver Spring Lockwood- Site Number : 8400042
Silver Spring, Maryland
University of Michigan Health System - Ann Arbor- Site Number : 8400014
Ann Arbor, Michigan
Clarkston Medical Group- Site Number : 8400054
Clarkston, Michigan
Javara - Mankato Clinic- Site Number : 8400001
Mankato, Minnesota
Mayo Clinic in Rochester - Minnesota- Site Number : 8400057
Rochester, Minnesota
Hannibal Regional Healthcare System- Site Number : 8400078
Hannibal, Missouri
Icahn School of Medicine at Mount Sinai (ISMMS) - Mount Sinai Doctors- Site Number : 8400069
New York, New York
Pioneer Clinical Research - New York- Site Number : 8400092
New York, New York
Piedmont Healthcare - Family Medicine- Site Number : 8400064
Statesville, North Carolina
Cleveland Clinic - Cleveland- Site Number : 8400106
Cleveland, Ohio
Asthma & Allergy Center - Toledo- Site Number : 8400020
Toledo, Ohio
OK Clinical Research- Site Number : 8400060
Edmond, Oklahoma
Showing 40 of 221 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.